Pharma Pulse: Walgreens’ New Hybrid Pharmacist Model, Pharmacies Expand Injectable Access, and More

Key Takeaways

• Walgreens hybrid model splits pharmacists between store and remote clinical duties
• Community pharmacies now deliver more vaccines and injectable therapies
• GoodRx‑Eli Lilly partnership adds cash‑pay GLP‑1 options nationwide
• Regeneron‑Telix deal signals multibillion‑dollar surge in radiopharma
• AbbVie secures Haisco assets outside China for up to $745 M

Pulse Analysis

Walgreens’ hybrid pharmacist model reflects a broader industry shift toward flexible workforce structures. By allowing pharmacists to divide time between patient‑facing counters and hub‑based clinical tasks, the retailer aims to mitigate staffing shortages while expanding medication therapy management services. This approach mirrors trends in telehealth and centralized pharmacy operations, positioning pharmacists as integral members of multidisciplinary care teams rather than solely dispensers.

Community pharmacies are increasingly becoming frontline venues for injectable medications, from routine vaccines to advanced GLP‑1 therapies. The GoodRx‑Eli Lilly collaboration exemplifies this evolution, offering cash‑pay pathways that bypass insurance hurdles and improve affordability for high‑cost metabolic drugs. Such direct‑to‑consumer models not only accelerate patient uptake but also reinforce pharmacies as critical access points for chronic disease management, especially in regions lacking robust primary‑care infrastructure.

The radiopharmaceutical sector is witnessing a surge of capital, highlighted by Regeneron’s multibillion‑dollar partnership with Telix to develop targeted cancer radioligands. This investment underscores confidence in precision oncology, where localized radiation delivery minimizes systemic toxicity. Concurrently, AbbVie’s $745 million licensing deal with Haisco expands its pipeline beyond Greater China, diversifying revenue streams and reinforcing its global growth strategy. Together, these moves illustrate a pharmaceutical landscape that values innovative delivery models, strategic collaborations, and geographic diversification to meet evolving patient needs.